86 related articles for article (PubMed ID: 9472838)
1. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
Khan A; Upton GV; Rudolph RL; Entsuah R; Leventer SM
J Clin Psychopharmacol; 1998 Feb; 18(1):19-25. PubMed ID: 9472838
[TBL] [Abstract][Full Text] [Related]
2. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.
Shea ML; Garfield LD; Teitelbaum S; Civitelli R; Mulsant BH; Reynolds CF; Dixon D; Doré P; Lenze EJ
Osteoporos Int; 2013 May; 24(5):1741-9. PubMed ID: 23358607
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.
Durand JP; Deplanque G; Montheil V; Gornet JM; Scotte F; Mir O; Cessot A; Coriat R; Raymond E; Mitry E; Herait P; Yataghene Y; Goldwasser F
Ann Oncol; 2012 Jan; 23(1):200-205. PubMed ID: 21427067
[TBL] [Abstract][Full Text] [Related]
4. The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders.
Ciraulo DA; Barlow DH; Gulliver SB; Farchione T; Morissette SB; Kamholz BW; Eisenmenger K; Brown B; Devine E; Brown TA; Knapp CM
Behav Res Ther; 2013 Nov; 51(11):729-35. PubMed ID: 24055681
[TBL] [Abstract][Full Text] [Related]
5. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study.
Brent D; Melhem N; Ferrell R; Emslie G; Wagner KD; Ryan N; Vitiello B; Birmaher B; Mayes T; Zelazny J; Onorato M; Devlin B; Clarke G; DeBar L; Keller M
Am J Psychiatry; 2010 Feb; 167(2):190-7. PubMed ID: 20008943
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled trial of venlafaxine to treat behavioural disorders in cats: a pilot study.
Metz D; Medam T; Masson S
J Feline Med Surg; 2022 Jun; 24(6):539-549. PubMed ID: 34420375
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate for patients with vascular depression accompanied by somatic symptoms: An open-labeled randomized control trial.
Chen H; Lin Y; Zhao Z; Lin T; Lin Q; Chen X; Wu W; Zeng G; Wu S; Liu N; Chen H; Chen R; Xiao Y
CNS Neurosci Ther; 2024 Mar; 30(3):e14650. PubMed ID: 38514905
[TBL] [Abstract][Full Text] [Related]
8. Differences between daily smokers, chippers, and nonsmokers with co-occurring anxiety and alcohol-use disorders.
Morissette SB; Gulliver SB; Kamholz BW; Duade J; Farchione T; Devine E; Brown TA; Barlow DH; Ciraulo D
Addict Behav; 2008 Nov; 33(11):1425-1431. PubMed ID: 18656314
[TBL] [Abstract][Full Text] [Related]
9. Unexplained recurrent high fever observed in a depressed adolescent.
Guo X; Li Y; Bai L; Lin F; Chen J; Zou T
BMC Psychiatry; 2024 Apr; 24(1):283. PubMed ID: 38627661
[TBL] [Abstract][Full Text] [Related]
10. Personalized venlafaxine dose prediction using artificial intelligence technology: a retrospective analysis based on real-world data.
Liu Y; Yu Z; Ye X; Zhang J; Hao X; Gao F; Yu J; Zhou C
Int J Clin Pharm; 2024 May; ():. PubMed ID: 38733475
[TBL] [Abstract][Full Text] [Related]
11. Time course of effects of venlafaxine on migraine and generalized pruritus in a patient with depression.
Miyahara Y; Funahashi H; Haruta-Tsukamoto A; Hidaka H; Fujimoto T; Horinouchi A; Nishimori T; Ishida Y
Clin Case Rep; 2021 Nov; 9(11):e05088. PubMed ID: 34815877
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.
Rudolph RL; Fabre LF; Feighner JP; Rickels K; Entsuah R; Derivan AT
J Clin Psychiatry; 1998 Mar; 59(3):116-22. PubMed ID: 9541154
[TBL] [Abstract][Full Text] [Related]
13. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.
Thase ME
J Clin Psychiatry; 1998 Oct; 59(10):502-8. PubMed ID: 9818630
[TBL] [Abstract][Full Text] [Related]
14. Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study.
Amsterdam JD; Hooper MB; Amchin J
J Clin Psychiatry; 1998 May; 59(5):236-40. PubMed ID: 9632034
[TBL] [Abstract][Full Text] [Related]
15. Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials.
Maslej MM; Furukawa TA; Cipriani A; Andrews PW; Mulsant BH
JAMA Psychiatry; 2020 Jun; 77(6):607-617. PubMed ID: 32074273
[TBL] [Abstract][Full Text] [Related]
16. Evidence-Based Clinical Vignettes from the Care Management Institute: Major Depression.
Price D
Perm J; 2002; 6(1):34-42. PubMed ID: 30313010
[No Abstract] [Full Text] [Related]
17. Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer.
Garcia S; Schuh M; Cheema A; Atwal H; Atwal PS
Case Rep Genet; 2017; 2017():6236714. PubMed ID: 29123929
[TBL] [Abstract][Full Text] [Related]
18. Mixed Anxiety and Depression : Diagnosis and Treatment Options.
Bakish D; Habib R; Hooper CL
CNS Drugs; 1998 Apr; 9(4):271-80. PubMed ID: 27521010
[TBL] [Abstract][Full Text] [Related]
19. The noradrenergic paradox: implications in the management of depression and anxiety.
Montoya A; Bruins R; Katzman MA; Blier P
Neuropsychiatr Dis Treat; 2016; 12():541-57. PubMed ID: 27042068
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan.
Higuchi T; Kamijima K; Nakagome K; Itamura R; Asami Y; Kuribayashi K; Imaeda T
Int Clin Psychopharmacol; 2016 Jan; 31(1):8-19. PubMed ID: 26513202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
